BioMedomics is a commercial-stage point-of-care diagnostics company, acquired by OraSure Technologies in November 2025, specializing in rapid tests for conditions like sickle cell disease. Its flagship product, Sickle SCAN®, is sold in over 40 countries, targeting critical gaps in healthcare access. The company leverages a robust IP portfolio and ISO-certified manufacturing to deliver lab-accurate results without complex equipment, aiming to advance health equity worldwide.
HematologyInfectious DiseasesOncologyWomen's Health
Technology Platform
Advanced immunoassay and lateral flow platform for point-of-care use, with expertise in hemoglobin diagnostics, antibody development, and integration of automation/AI.
Funding History
10
Total raised:$14.3M
Grant$1.8MCenters for Disease Control and Prevention
Series A$10MUndisclosed
Grant$496KNHLBI
Grant$496KNHLBI
Opportunities
Massive global need for decentralized testing in sickle cell disease, particularly in WHO-priority countries launching screening programs.
Expansion into infectious disease diagnostics, leveraging OraSure's expertise and distribution, opens large adjacent markets.
The growing trend towards point-of-care testing across all healthcare settings provides a long-term tailwind.
Risk Factors
Integration challenges following the OraSure acquisition could disrupt operations.
The competitive POC diagnostics landscape and risk of technological obsolescence require continuous innovation.
Regulatory hurdles and securing reimbursement in diverse global markets remain key execution risks.
Competitive Landscape
Competes in the crowded point-of-care diagnostics market against large players like Abbott, Roche, and BD, as well as specialized hematology and sickle cell diagnostic companies. Its first-mover advantage with Sickle SCAN® is a key differentiator, but maintaining leadership requires ongoing product development and commercial execution.
